Page 10 - Refractory Multiple News Today

Data presented at ASH 2021 congress show 83 percent of patients achieved a stringent complete response at median follow-up of 22 months1 92 percent of evaluable patients achieved minimal residual

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating...

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with...

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with...

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human...

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human...

Data from preclinical studies in collaboration with Fred Hutchinson Cancer Research Center will be presented at ASH and provide strong rationale for use of EOS-448 as a single agent and in combination

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of...

After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the

 After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutica...